Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mecapegfilgrastim Primary Prevention of Neutropenia in Solid Tumor Patients Under Standardized Nutritional Intervention
ChiCTR2500115702Phase 4Recruiting
- Sponsor
- Anqing First People's Hospital
- Start
- Dec 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of mecapegfilgrastim in neutropenia and febrile neutropenia (FN) (2 arms), sponsored by Anqing First People's Hospital. Primary endpoint: The incidence and duration of neutropenia at grade 3/4. Started Dec 2025; status: recruiting.
02
Drugs
mecapegfilgrastim
03
Conditions
neutropeniafebrile neutropenia (FN)
Beyond the preview
Go deeper on ChiCTR2500115702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500115702.